« Home Research About Contact Us

Neurosearch -USA

Change the future with us

Parkinson's
Disease
Multiple
sclerosis
Alzheimer's
Disease
Post-Ischemic
Stroke


Learn about


Neuro-Diseases
Media
Facts

LEARNING PANEL


MULTIPLE SCLEROSIS


ANTI-CD20

 

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). MS is an autoimmune disease that causes inflammation of the insulating membranes (myelin) that surround nerves within the central nervous system. In RRMS, there are clear episodes of inflammatory activity (relapses).


Do you or a loved one have..

What does it mean?

    You or loved one have been previously treated for relapsing forms of Multiple Sclerosis (RMS).

How long is the study?

    The study may involve 18 to 24 visits or more to the study site for up to 48 weeks. The time you will spend in the study will depend on the number of days you are able to complete. Approximately 24 men and women with RMS, ages 18 and over, may participate in this study.

How to participate?

    Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

You must be..

  • 18-55 of age
  • ≥ 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 Gd enhancing lesion
  • B cell counts ≥5% of total lymphocytes
  • Active disease
  • Neurologic stability ≥ 30 days prior to screening and baseline
  • Willingness and ability to comply with trial and follow-up procedures, give written consent
  • But cannot be..

  • Treatment with Anti-CD20 or other B cell directed treatment within last 12 months
  • Treated with alemtuzumab within the last 12 months prior to screening
  • Pregnant or nursing
  • Current evidence or known history of clinically significant infection including : a. Chronic or ongoing active infectious disease requiring long term systemic treatment such as, but not limited to: PML, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis (TB), or active hepatitis C b. Previous serious opportunistic or atypical infections c. History of positive serology for hepatitis B or HIV
  •  

    if you are interested or someone you know that might be eligible, fill out our survey form here